|
Name |
13-Oxofumitremorgin B
|
| Molecular Formula | C27H31N3O5 | |
| IUPAC Name* |
(1R,12S,15S)-1-hydroxy-7-methoxy-10-(3-methylbut-2-enyl)-12-(2-methylprop-1-enyl)-10,13,19-triazapentacyclo[11.7.0.03,11.04,9.015,19]icosa-3(11),4(9),5,7-tetraene-2,14,20-trione
|
|
| SMILES |
CC(=CCN1C2=C(C=CC(=C2)OC)C3=C1[C@@H](N4C(=O)[C@@H]5CCCN5C(=O)[C@@]4(C3=O)O)C=C(C)C)C
|
|
| InChI |
InChI=1S/C27H31N3O5/c1-15(2)10-12-28-20-14-17(35-5)8-9-18(20)22-23(28)21(13-16(3)4)30-25(32)19-7-6-11-29(19)26(33)27(30,34)24(22)31/h8-10,13-14,19,21,34H,6-7,11-12H2,1-5H3/t19-,21-,27+/m0/s1
|
|
| InChIKey |
PKXCLEPXRNTYPU-BKCZMFJTSA-N
|
|
| Synonyms |
13-Oxofumitremorgin B; (1R,12S,15S)-1-hydroxy-7-methoxy-10-(3-methylbut-2-enyl)-12-(2-methylprop-1-enyl)-10,13,19-triazapentacyclo[11.7.0.03,11.04,9.015,19]icosa-3(11),4(9),5,7-tetraene-2,14,20-trione; 1,2,3,11,12,14abeta-Hexahydro-5abeta-hydroxy-9-methoxy-11-(3-methyl-2-butenyl)-12alpha-(2-methyl-1-propenyl)-5H,14H-pyrrolo[1'',2'':4',5']pyrazino[1',2':1,6]pyrido[3,4-b]indole-5,6,14(5aH)-trione; 4IL
|
|
| CAS | NA | |
| PubChem CID | 102583557 | |
| ChEMBL ID | NA |
Chemical Classification: |
|
|
|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
|---|---|---|---|---|---|---|---|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
| Molecular Weight: | 477.6 | ALogp: | 3.5 |
| HBD: | 1 | HBA: | 5 |
| Rotatable Bonds: | 4 | Lipinski's rule of five: | Accepted |
| Polar Surface Area: | 92.1 | Aromatic Rings: | 5 |
| Heavy Atoms: | 35 | QED Weighted: | 0.529 |
| Caco-2 Permeability: | -4.881 | MDCK Permeability: | 0.00001380 |
| Pgp-inhibitor: | 0.992 | Pgp-substrate: | 0.635 |
| Human Intestinal Absorption (HIA): | 0.763 | 20% Bioavailability (F20%): | 0.014 |
| 30% Bioavailability (F30%): | 0.96 |
| Blood-Brain-Barrier Penetration (BBB): | 0.75 | Plasma Protein Binding (PPB): | 88.53% |
| Volume Distribution (VD): | 1.385 | Fu: | 6.12% |
| CYP1A2-inhibitor: | 0.039 | CYP1A2-substrate: | 0.093 |
| CYP2C19-inhibitor: | 0.917 | CYP2C19-substrate: | 0.908 |
| CYP2C9-inhibitor: | 0.931 | CYP2C9-substrate: | 0.303 |
| CYP2D6-inhibitor: | 0.016 | CYP2D6-substrate: | 0.124 |
| CYP3A4-inhibitor: | 0.912 | CYP3A4-substrate: | 0.947 |
| Clearance (CL): | 8.844 | Half-life (T1/2): | 0.06 |
| hERG Blockers: | 0.035 | Human Hepatotoxicity (H-HT): | 0.983 |
| Drug-inuced Liver Injury (DILI): | 0.99 | AMES Toxicity: | 0.017 |
| Rat Oral Acute Toxicity: | 0.009 | Maximum Recommended Daily Dose: | 0.948 |
| Skin Sensitization: | 0.184 | Carcinogencity: | 0.644 |
| Eye Corrosion: | 0.003 | Eye Irritation: | 0.006 |
| Respiratory Toxicity: | 0.885 |
| Similar NPs | Similar Drugs | ||||||
|---|---|---|---|---|---|---|---|
| NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
| ENC000837 | ![]() |
0.761 | D06YFA | ![]() |
0.272 | ||
| ENC002042 | ![]() |
0.540 | D0W6DG | ![]() |
0.262 | ||
| ENC000842 | ![]() |
0.536 | D02IQY | ![]() |
0.250 | ||
| ENC001958 | ![]() |
0.530 | D0Y5RZ | ![]() |
0.247 | ||
| ENC003264 | ![]() |
0.530 | D01TSI | ![]() |
0.244 | ||
| ENC003265 | ![]() |
0.529 | D06HBQ | ![]() |
0.244 | ||
| ENC002260 | ![]() |
0.500 | D0F4ZY | ![]() |
0.236 | ||
| ENC005479 | ![]() |
0.496 | D0R1RS | ![]() |
0.231 | ||
| ENC001060 | ![]() |
0.458 | D09NNH | ![]() |
0.231 | ||
| ENC002274 | ![]() |
0.458 | D0V3ZA | ![]() |
0.230 | ||